FibroBiologics Inc. (FBLG)
FBLG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | FBLG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001958777 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements." | 10-Q 2026-07-31 |
| Cash and burn | $3.5M cash; operating cash flow -$3.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 6,658,193 (2026-07-31); 41,889,142 a year earlier. 1y figure adjusted for split (1-for-20 overall). | Cover page 2026-07-31 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-03-30 | Source 2026-03-30 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-05-06 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-07-24 |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States | PCAOB Form AP 2026-02-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $120K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.1M | -$3.3M | $3.5M | $124K | Needs four quarters | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | Not filed | -$5.0M | -$4.4M | $1.5M | $246K | Needs four quarters | 10-Q 2026-07-31 |
| Q4 2025 2025-12-31 | Not filed | -$3.2M | -$3.2M | $4.9M | $11.6M | Needs four quarters | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | Not filed | -$5.8M | -$4.0M | $4.9M | $14.3M | Needs four quarters | 10-Q 2025-10-31 |
| Q2 2025 2025-06-30 | Not filed | -$4.7M | -$4.0M | $8.8M | $13.9M | Needs four quarters | 10-Q 2026-07-31 |
| Q1 2025 2025-03-31 | Not filed | -$5.0M | -$5.3M | $8.7M | $9.4M | Needs four quarters | 10-Q 2026-07-31 |
| Q4 2024 2024-12-31 | Not filed | -$3.1M | -$3.1M | $14.0M | $19.2M | Needs four quarters | 10-K 2026-02-24 |
| Q3 2024 2024-09-30 | Not filed | -$500K | -$2.6M | $7.8M | $115K | Needs four quarters | 10-Q 2025-10-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-10-13 |
| Latest annual report | 10-K/A | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-10-08 |
| Latest proxy | DEFA14A | 2026-09-09 |
Source: SEC EDGAR submissions feed, 244 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.4% |
| 1 month | -3.4% |
| 3 months | -19.4% |
| Year to date | -79.4% |
| 1 year | -86.2% |
| From 52-week high | -89.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
| APRE | Aprea Therapeutics Inc. | $0.4063 | -2.38% | $5.8M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
| BLRX | BioLineRx Ltd. | $1.15 | -12.61% | $5.7M |
| ALZN | Alzamend Neuro Inc. | $1.18 | -4.84% | $5.7M |
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier